[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.234.223.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Dossett  LA, Riesel  JN, Griffin  MR, Cotton  BA.  Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank.  Arch Surg. 2011;146(5):565-570.PubMedGoogle ScholarCrossref
2.
Keeling  D, Baglin  T, Tait  C,  et al; British Committee for Standards in Haematology.  Guidelines on oral anticoagulation with warfarin—fourth edition.  Br J Haematol. 2011;154(3):311-324.PubMedGoogle ScholarCrossref
3.
Tadros  R, Shakib  S.  Warfarin—indications, risks and drug interactions.  Aust Fam Physician. 2010;39(7):476-479.PubMedGoogle Scholar
4.
Kirane  A, Ludwig  KF, Sorrelle  N,  et al.  Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis.  Cancer Res. 2015;75(18):3699-3705.PubMedGoogle ScholarCrossref
5.
Ryan  JJ, Ketcham  AS, Wexler  H.  Reduced incidence of spontaneous metastases with long-term Coumadin therapy.  Ann Surg. 1968;168(1):163-168.PubMedGoogle ScholarCrossref
6.
Paolino  M, Choidas  A, Wallner  S,  et al.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.  Nature. 2014;507(7493):508-512.PubMedGoogle ScholarCrossref
7.
Williamson  RC, Lyndon  PJ, Tudway  AJ.  Effects of anticoagulation and ileal resection on the development and spread of experimental intestinal carcinomas.  Br J Cancer. 1980;42(1):85-94.PubMedGoogle ScholarCrossref
8.
Tagalakis  V, Tamim  H, Blostein  M, Collet  JP, Hanley  JA, Kahn  SR.  Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study.  Lancet Oncol. 2007;8(5):395-402.PubMedGoogle ScholarCrossref
9.
Kinnunen  PT, Murtola  TJ, Talala  K, Taari  K, Tammela  TL, Auvinen  A.  Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.  Scand J Urol. 2016;50(6):413-419.PubMedGoogle ScholarCrossref
10.
Rajotte  I, Hasanbasic  I, Blostein  M.  Gas6-mediated signaling is dependent on the engagement of its gamma-carboxyglutamic acid domain with phosphatidylserine.  Biochem Biophys Res Commun. 2008;376(1):70-73.PubMedGoogle ScholarCrossref
11.
Tie  JK, Jin  DY, Stafford  DW.  Conserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regeneration.  J Biol Chem. 2014;289(13):9396-9407.PubMedGoogle ScholarCrossref
12.
Hirsh  J, Dalen  J, Anderson  DR,  et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest. 2001;119(1)(suppl):8S-21S.PubMedGoogle ScholarCrossref
13.
Cranenburg  EC, Schurgers  LJ, Vermeer  C.  Vitamin K: the coagulation vitamin that became omnipotent.  Thromb Haemost. 2007;98(1):120-125.PubMedGoogle Scholar
14.
Davra  V, Kimani  SG, Calianese  D, Birge  RB.  Ligand activation of TAM family receptors—implications for tumor biology and therapeutic response.  Cancers (Basel). 2016;8(12):E107.PubMedGoogle ScholarCrossref
15.
Skiri  H. Role and status of civil registration (population registration) and vital statistics systems in Norway. Statistics Norway. https://unstats.un.org/unsd/vitalstatkb/KnowledgebaseArticle50247.aspx. Published October 1995. Accessed September 11, 2017.
16.
Larsen  IK, Småstuen  M, Johannesen  TB,  et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.  Eur J Cancer. 2009;45(7):1218-1231.PubMedGoogle ScholarCrossref
17.
Furu  K.  Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway.  Nor Epidemiol. 2008;18(2):129-136. doi:10.5324/nje.v18i2.23Google Scholar
18.
Fine  JP, Gray  RJ.  A proportional hazards model for the subdistribution of a competing risk.  J Am Stat Assoc. 1999;94(446):496-509.Google ScholarCrossref
19.
Kumana  CR, Cheung  BM, Siu  DC, Tse  HF, Lauder  IJ.  Non-vitamin K oral anticoagulants versus warfarin for patients with atrial fibrillation: absolute benefit and harm assessments yield novel insights.  Cardiovasc Ther. 2016;34(2):100-106.PubMedGoogle ScholarCrossref
20.
Sørensen  HT, Mellemkjaer  L, Steffensen  FH, Olsen  JH, Nielsen  GL.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.  N Engl J Med. 1998;338(17):1169-1173.PubMedGoogle ScholarCrossref
21.
Baron  JA, Gridley  G, Weiderpass  E, Nyrén  O, Linet  M.  Venous thromboembolism and cancer.  Lancet. 1998;351(9109):1077-1080.PubMedGoogle ScholarCrossref
22.
Björck  F, Ek  A, Johansson  L, Själander  A.  Warfarin persistence among atrial fibrillation patients—why is treatment ended?  Cardiovasc Ther. 2016;34(6):468-474.PubMedGoogle ScholarCrossref
23.
Rothlin  CV, Carrera-Silva  EA, Bosurgi  L, Ghosh  S.  TAM receptor signaling in immune homeostasis.  Annu Rev Immunol. 2015;33:355-391.PubMedGoogle ScholarCrossref
24.
Gjerdrum  C, Tiron  C, Høiby  T,  et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.  Proc Natl Acad Sci U S A. 2010;107(3):1124-1129.PubMedGoogle ScholarCrossref
25.
Liu  W, Li  L, Xu  J, Zhang  C.  Pharmaceutical care for a patient with warfarin-induced autoimmune hepatitis  [in Chinese].  Beijing Da Xue Xue Bao. 2016;48(1):183-186.PubMedGoogle Scholar
26.
Bobek  V, Kovarík  J.  Antitumor and antimetastatic effect of warfarin and heparins.  Biomed Pharmacother. 2004;58(4):213-219.PubMedGoogle ScholarCrossref
27.
Paccez  JD, Vogelsang  M, Parker  MI, Zerbini  LF.  The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.  Int J Cancer. 2014;134(5):1024-1033.PubMedGoogle ScholarCrossref
28.
Conen  D, Wong  JA, Sandhu  RK,  et al.  Risk of malignant cancer among women with new-onset atrial fibrillation.  JAMA Cardiol. 2016;1(4):389-396.PubMedGoogle ScholarCrossref
29.
Tsan  YT, Lee  CH, Ho  WC, Lin  MH, Wang  JD, Chen  PC.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection.  J Clin Oncol. 2013;31(12):1514-1521.PubMedGoogle ScholarCrossref
30.
Barron  TI, Connolly  RM, Sharp  L, Bennett  K, Visvanathan  K.  Beta blockers and breast cancer mortality: a population-based study.  J Clin Oncol. 2011;29(19):2635-2644.PubMedGoogle ScholarCrossref
31.
Tagalakis  V, Blostein  M, Robinson-Cohen  C, Kahn  SR.  The effect of anticoagulants on cancer risk and survival: systematic review.  Cancer Treat Rev. 2007;33(4):358-368.PubMedGoogle ScholarCrossref
32.
Schulman  S, Lindmarker  P.  Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: duration of anticoagulation trial.  N Engl J Med. 2000;342(26):1953-1958.PubMedGoogle ScholarCrossref
33.
Taliani  MR, Agnelli  G, Prandoni  P,  et al; Warfarin Optimal Duration Italian Trial (WODIT) Investigators.  Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation.  J Thromb Haemost. 2003;1(8):1730-1733.PubMedGoogle ScholarCrossref
34.
Blumentals  WA, Foulis  PR, Schwartz  SW, Mason  TJ.  Does warfarin therapy influence the risk of bladder cancer?  Thromb Haemost. 2004;91(4):801-805.PubMedGoogle Scholar
Original Investigation
December 2017

Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years

Author Affiliations
  • 1Department of Biomedicine, University of Bergen, Bergen, Norway
  • 2Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
  • 3Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway
  • 4Clinical Institute 1, University of Bergen, Bergen, Norway
  • 5Department of Oncology, Haukeland University Hospital, Bergen, Norway
JAMA Intern Med. 2017;177(12):1774-1780. doi:10.1001/jamainternmed.2017.5512
Key Points

Question  Is warfarin use a protective factor for cancer?

Findings  In this population-based cohort study of 1 256 725 persons, there was a significantly lower age- and sex-adjusted incidence rate ratio of cancer among warfarin users vs nonusers.

Meaning  Warfarin, used by millions of adults worldwide, may be associated with lower cancer incidence across a broad range of malignant neoplasms.

Abstract

Importance  In cancer models, warfarin inhibits AXL receptor tyrosine kinase–dependent tumorigenesis and enhances antitumor immune responses at doses not reaching anticoagulation levels. This study investigates the association between warfarin use and cancer incidence in a large, unselected population-based cohort.

Objective  To examine the association between warfarin use and cancer incidence.

Design, Setting, and Participants  This population-based cohort study with subgroup analysis used the Norwegian National Registry coupled with the Norwegian Prescription Database and the Cancer Registry of Norway. The cohort comprised all persons (N = 1 256 725) born between January 1, 1924, and December 31, 1954, who were residing in Norway from January 1, 2006, through December 31, 2012. The cohort was divided into 2 groups—warfarin users and nonusers; persons taking warfarin for atrial fibrillation or atrial flutter were the subgroup. Data were collected from January 1, 2004, to December 31, 2012. Data analysis was conducted from October 15, 2016, to January 31, 2017.

Exposures  Warfarin use was defined as taking at least 6 months of a prescription and at least 2 years from first prescription to any cancer diagnosis. If warfarin treatment started after January 1, 2006, each person contributed person-time in the nonuser group until the warfarin user criteria were fulfilled.

Main Outcomes and Measures  Cancer diagnosis of any type during the 7-year observation period (January 1, 2006, through December 31, 2012).

Results  Of the 1 256 725 persons in the cohort, 607 350 (48.3%) were male, 649 375 (51.7%) were female, 132 687 (10.6%) had cancer, 92 942 (7.4%) were classified as warfarin users, and 1 163 783 (92.6%) were classified as nonusers. Warfarin users were older, with a mean (SD) age of 70.2 (8.2) years, and were predominantly men (57 370 [61.7%]) as compared with nonusers, who had a mean (SD) age of 63.9 (8.6) years and were mostly women (613 803 [52.7%]). Among warfarin users and compared with nonusers, there was a significantly lower age- and sex-adjusted incidence rate ratio (IRR) in all cancer sites (IRR, 0.84; 95% CI, 0.82-0.86) and in prevalent organ-specific sites (lung, 0.80 [95% CI, 0.75-0.86]; prostate, 0.69 [95% CI, 0.65-0.72]; and breast, 0.90 [95% CI, 0.82-1.00]). There was no observed significant effect in colon cancer (IRR, 0.99; 95% CI, 0.93-1.06). In a subgroup analysis of patients with atrial fibrillation or atrial flutter, the IRR was lower in all cancer sites (IRR, 0.62; 95% CI, 0.59-0.65) and in prevalent sites (lung, 0.39 [95% CI, 0.33-0.46]; prostate, 0.60 [95% CI, 0.55-0.66]; breast, 0.72 [95% CI, 0.59-0.87]; and colon, 0.71 [95% CI, 0.63-0.81]).

Conclusions and Relevance  Warfarin use may have broad anticancer potential in a large, population-based cohort of persons older than 50 years. This finding could have important implications for the selection of medications for patients needing anticoagulation.

×